Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
|Videos|May 24, 2011
Donna Berry Discusses Her Prostate Cancer Research
Author(s)Donna L. Berry, PhD, RN
Donna Berry Discusses Her Prostate Cancer Research
Advertisement
Donna Berry, PhD, RN, AOCN®, FAAN, from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute discusses her prostate cancer research titled Personal Patient Profile-Prostate a web-based program that has individuals complete a touch-screen survey and receive multimedia treatment information and guidance tailored to their responses.
Advertisement
Related to this article
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Mark Garzotto, MD, discusses data with aglatimagene besadenovec plus valacyclovir and EBRT in intermediate- to high-risk localized prostate cancer.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.
The addition of olaparib to radium‐223 did not significantly impact PROs compared with radium‐223 alone in mCRPC with bone metastases.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
3
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
4
Dr Mardones on Giredestrant Plus Palbociclib in Estrogen Receptor+ Breast Cancer
5